Related Experiment Video
Updated: May 17, 2026
05:45
Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
Brazilian National System for the Monitoring and Improvement of Compounding Practices: program outcomes
Hugo Guedes de Souza1, Alvaro Favaro, Alba Lívia Andrade
1Brazilian National Association of Compounding Pharmacies (ANFARMAG), São Paulo, SP, Brazil.
International Journal of Pharmaceutical Compounding
|October 12, 2012
Summary
The National System for the Monitoring and Improvement of Compounding Practices in Brazil helped pharmacies meet strict regulations. Participation significantly improved drug manufacturing processes and preparation quality in the compounding sector.
Area of Science:
- Pharmaceutical Sciences
- Regulatory Affairs
- Quality Management
Background:
- Brazilian compounding pharmacies face stringent drug manufacturing regulations.
- A national system was developed to address compliance and quality challenges.
Purpose of the Study:
- To report the results of the National System for the Monitoring and Improvement of Compounding Practices in Brazil (2006-2010).
- To present new developments in the 2011 cycle of the program.
- To evaluate the impact of the system on pharmacy practices and drug quality.
Main Methods:
- Implementation of a process-focused national monitoring and improvement program.
- Analysis of data from the first three editions (2006-2010) and the 2011 cycle.
- Assessment of pharmacy compliance and preparation quality.
Main Results:
- Participation in the national system led to improved legal compliance for pharmacies.
- Significant enhancements in the quality of compounded drug preparations were observed.
- The program facilitated the achievement of unprecedented quality standards in Brazil's compounding sector.
Conclusions:
- The National System for the Monitoring and Improvement of Compounding Practices in Brazil is effective in enhancing regulatory compliance.
- The program demonstrably improves the quality of compounded medications.
- Sustained participation fosters a culture of continuous quality improvement in pharmaceutical compounding.
Related Concept Videos
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:11Guidelines for Writing Outcome
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...